Related Experiment Video

Updated: May 11, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Colistin Therapy in a 23-Week Gestational-Age Neonate with Multidrug-Resistant Acinetobacter baumannii Pneumonia

Mirjana Lulic-Botica1, Lilia Dejesus

  • 1Pharmacy Department, Hutzel Women's Hospital, Wayne State University, Detroit, Michigan.

AJP Reports
|May 25, 2013
PubMed

Insights

This study reports the first use of colistimethate sodium in a premature infant with a multidrug-resistant bacterial pneumonia. The treatment was associated with acute kidney injury and seizures.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Rising rates of multidrug-resistant pathogens necessitate the re-evaluation of older antibiotics.
  • Acinetobacter baumannii is a significant cause of hospital-acquired infections, particularly in vulnerable populations.

Observation:

  • A 23-week gestational-age neonate presented with pneumonia caused by multidrug-resistant Acinetobacter baumannii.
  • Colistimethate sodium was initiated for treatment due to limited therapeutic options.

Findings:

  • This case represents the first documented instance of colistimethate sodium administration in such a young neonate.
  • The neonate experienced acute renal failure and seizures following the commencement of colistimethate sodium therapy.

Implications:

  • This case underscores the potential nephrotoxic and neurotoxic effects of colistimethate sodium in extremely premature neonates.
  • Further research is warranted to establish safe and effective dosing strategies and to monitor for adverse events in this population.
Keywords:
Colistimethateextremely low-birth-weightmultidrug resistantneonate

More Related Videos

Galleria mellonella as an Antimicrobial Screening Model06:19

Galleria mellonella as an Antimicrobial Screening Model

Published on: October 11, 2024

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: